Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CDMO NASDAQ:EOLS NASDAQ:KIN NASDAQ:MRSN NASDAQ:PBYI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCDMOAvid Bioservices$12.50+0.1%$12.50$8.74▼$12.51$799.18M1.391.45 million shs3.07 million shsEOLSEvolus$6.68+0.8%$8.03$5.71▼$17.82$432.39M1.071.08 million shs61,875 shsKINKindred Biosciences$9.25$9.22$3.46▼$9.28$420.52M1.3840,890 shs178,496 shsMRSNMersana Therapeutics$7.29+1.7%$7.55$5.21▼$70.75$36.38M0.86150,600 shs2,559 shsPBYIPuma Biotechnology$4.58-1.4%$4.21$2.32▼$6.07$230.54M1.37482,334 shs74,797 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCDMOAvid Bioservices0.00%0.00%0.00%0.00%+11.96%EOLSEvolus-7.79%-12.88%-1.49%-28.32%-62.09%KINKindred Biosciences0.00%0.00%0.00%0.00%0.00%MRSNMersana Therapeutics+0.42%+1.85%+0.14%-18.85%-86.41%PBYIPuma Biotechnology+3.80%+1.75%-19.02%+35.28%+83.40%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCDMOAvid Bioservices$12.50+0.1%$12.50$8.74▼$12.51$799.18M1.391.45 million shs3.07 million shsEOLSEvolus$6.68+0.8%$8.03$5.71▼$17.82$432.39M1.071.08 million shs61,875 shsKINKindred Biosciences$9.25$9.22$3.46▼$9.28$420.52M1.3840,890 shs178,496 shsMRSNMersana Therapeutics$7.29+1.7%$7.55$5.21▼$70.75$36.38M0.86150,600 shs2,559 shsPBYIPuma Biotechnology$4.58-1.4%$4.21$2.32▼$6.07$230.54M1.37482,334 shs74,797 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCDMOAvid Bioservices0.00%0.00%0.00%0.00%+11.96%EOLSEvolus-7.79%-12.88%-1.49%-28.32%-62.09%KINKindred Biosciences0.00%0.00%0.00%0.00%0.00%MRSNMersana Therapeutics+0.42%+1.85%+0.14%-18.85%-86.41%PBYIPuma Biotechnology+3.80%+1.75%-19.02%+35.28%+83.40%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCDMOAvid Bioservices 2.00Hold$12.500.04% UpsideEOLSEvolus 2.75Moderate Buy$21.25220.51% UpsideKINKindred Biosciences 0.00N/AN/AN/AMRSNMersana Therapeutics 3.00Buy$56.60689.40% UpsidePBYIPuma Biotechnology 3.00Buy$7.0050.86% UpsideCurrent Analyst Ratings BreakdownLatest PBYI, EOLS, KIN, MRSN, and CDMO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/8/2025EOLSEvolusBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$18.008/14/2025MRSNMersana TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$250.00 ➝ $36.008/14/2025MRSNMersana TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$125.00 ➝ $30.008/13/2025MRSNMersana TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$17.008/6/2025EOLSEvolusBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$21.00 ➝ $18.008/6/2025EOLSEvolusHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$27.00 ➝ $20.008/6/2025EOLSEvolusNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Hold$22.00(Data available from 9/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCDMOAvid Bioservices$139.91M5.71$0.15 per share80.92$3.02 per share4.14EOLSEvolus$266.27M1.61N/AN/A$0.09 per share73.67KINKindred Biosciences$42.16M9.97N/AN/A$1.75 per share5.29MRSNMersana Therapeutics$40.50M0.88N/AN/A($1.92) per share-3.73PBYIPuma Biotechnology$230.50M1.01$0.88 per share5.25$1.88 per share2.47Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCDMOAvid Bioservices-$140.75M-$2.39N/AN/AN/A-101.07%-33.18%-8.45%N/AEOLSEvolus-$50.42M-$0.98N/AN/AN/A-22.31%-759.04%-24.63%11/5/2025 (Estimated)KINKindred Biosciences-$21.80M-$0.55N/AN/AN/A-529.26%-54.19%-39.76%N/AMRSNMersana Therapeutics-$69.19M-$14.62N/AN/AN/A-212.94%-990.16%-54.85%11/12/2025 (Estimated)PBYIPuma Biotechnology$30.28M$0.984.7312.21N/A20.38%53.15%23.51%11/6/2025 (Estimated)Latest PBYI, EOLS, KIN, MRSN, and CDMO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025MRSNMersana Therapeutics-$3.75-$4.08-$0.33-$4.87$6.06 million$3.06 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCDMOAvid BioservicesN/AN/AN/AN/AN/AEOLSEvolusN/AN/AN/AN/AN/AKINKindred BiosciencesN/AN/AN/AN/AN/AMRSNMersana TherapeuticsN/AN/AN/AN/AN/APBYIPuma BiotechnologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCDMOAvid Bioservices3.581.300.92EOLSEvolus22.002.271.86KINKindred Biosciences0.197.027.02MRSNMersana TherapeuticsN/A1.351.35PBYIPuma Biotechnology0.101.731.62Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCDMOAvid Bioservices97.16%EOLSEvolus90.69%KINKindred Biosciences66.89%MRSNMersana Therapeutics93.92%PBYIPuma Biotechnology61.29%Insider OwnershipCompanyInsider OwnershipCDMOAvid Bioservices3.05%EOLSEvolus6.10%KINKindred Biosciences13.69%MRSNMersana Therapeutics13.00%PBYIPuma Biotechnology23.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCDMOAvid Bioservices32063.96 million62.01 millionOptionableEOLSEvolus17064.68 million60.74 millionOptionableKINKindred Biosciences6345.46 millionN/AOptionableMRSNMersana Therapeutics1504.99 million4.34 millionOptionablePBYIPuma Biotechnology20050.37 million38.64 millionOptionablePBYI, EOLS, KIN, MRSN, and CDMO HeadlinesRecent News About These CompaniesPBYI Surges 30% in 3 Months: How Should You Play the Stock?September 15 at 1:46 PM | zacks.com79,101 Shares in Puma Biotechnology, Inc. $PBYI Bought by Nuveen LLCSeptember 8, 2025 | marketbeat.comPuma Biotechnology (NASDAQ:PBYI) Rating Increased to Strong-Buy at Wall Street ZenSeptember 8, 2025 | marketbeat.comAre Strong Financial Prospects The Force That Is Driving The Momentum In Puma Biotechnology, Inc.'s NASDAQ:PBYI) Stock?September 4, 2025 | finance.yahoo.comPuma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)September 4, 2025 | businesswire.comPuma Biotechnology to Present at the H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 2, 2025 | businesswire.comAmerican Century Companies Inc. Has $3.40 Million Holdings in Puma Biotechnology, Inc. $PBYISeptember 2, 2025 | marketbeat.comPuma Biotech (PBYI) May Find a Bottom Soon, Here's Why You Should Buy the Stock NowSeptember 1, 2025 | zacks.comShould Value Investors Buy Puma Biotechnology (PBYI) Stock?August 28, 2025 | zacks.comVirtus Advisers LLC Makes New Investment in Puma Biotechnology, Inc. $PBYIAugust 27, 2025 | marketbeat.comPuma Biotechnology (NASDAQ:PBYI) Upgraded by Wall Street Zen to Buy RatingAugust 18, 2025 | marketbeat.comConnor Clark & Lunn Investment Management Ltd. Boosts Stock Holdings in Puma Biotechnology, Inc. (NASDAQ:PBYI)August 16, 2025 | marketbeat.comAdditional Considerations Required While Assessing Puma Biotechnology's (NASDAQ:PBYI) Strong EarningsAugust 15, 2025 | finance.yahoo.comPuma Biotechnology Reports Strong Q2 2025 EarningsAugust 13, 2025 | msn.comBarclays Maintains a Sell Rating on Puma Biotechnology (PBYI) With a $2 PTAugust 12, 2025 | msn.comShould Value Investors Buy Puma Biotechnology (PBYI) Stock?August 12, 2025 | zacks.comPuma Biotechnology, Inc. (PBYI) Soars to 52-Week High, Time to Cash Out?August 12, 2025 | zacks.comResults: Puma Biotechnology, Inc. Beat Earnings Expectations And Analysts Now Have New ForecastsAugust 10, 2025 | finance.yahoo.comPuma Biotechnology, Inc. (NASDAQ:PBYI) Q2 2025 Earnings Call TranscriptAugust 9, 2025 | msn.comPBYI's Q2 Earnings Beat Estimates, Nerlynx Sales Drive RevenuesAugust 8, 2025 | zacks.comPuma (PBYI) Q2 Revenue Rises 11%August 8, 2025 | fool.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Tariff-Proof Retailers Making New All-time HighsBy Dan Schmidt | September 1, 2025Intel's Silent Comeback: 3 Pillars the Market Is OverlookingBy Jeffrey Neal Johnson | September 12, 2025Is Viking’s Growth Still Worth the Premium?By Chris Markoch | August 20, 2025Big Analyst Revisions Could Be Ahead for SoFi StockBy Gabriel Osorio-Mazilli | August 26, 2025PBYI, EOLS, KIN, MRSN, and CDMO Company DescriptionsAvid Bioservices NASDAQ:CDMOAvid Bioservices, Inc. operates as a contract development and manufacturing organization for the biotechnology and biopharmaceutical industries in the United States. It provides process development and current good manufacturing practice clinical and commercial manufacturing services of biologics, including clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, regulatory submission and support, upstream and downstream development and optimization, analytical methods development, cell line development, testing, and characterization services. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was incorporated in 1981 and is based in Tustin, California.Evolus NASDAQ:EOLS$6.68 +0.05 (+0.75%) As of 10:18 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.Kindred Biosciences NASDAQ:KINKindred Biosciences, Inc. is a development-stage biopharmaceutical company, which focuses on saving and improving the lives of pets. The company was founded by Richard Chin and Denise M. Bevers on September 25, 2012 and is headquartered in Burlingame, CA.Mersana Therapeutics NASDAQ:MRSN$7.29 +0.12 (+1.67%) As of 10:18 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.Puma Biotechnology NASDAQ:PBYI$4.58 -0.06 (-1.36%) As of 10:19 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Lululemon’s Sell-Off Looks Overdone: A Contrarian Case Palantir’s Commercial Growth Story Is Just Getting Started How Bath & Body Works Is a Perfect Example of a Value Stock The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Why Opendoor Stock Is Soaring—and May Just Be Starting Reddit Hits Record Highs: Why Wall Street Is Taking Notice Royal Caribbean's 33% Dividend Hike Signals Deeper Growth Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
